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Figure 1. Cumulative incidence of relapse by CTRA gene proﬁle.
Figure 2. Probability of leukemia free survival by CTRA gene proﬁle.
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Background: Previous research suggests that patients
treated with HCT often experience elevated levels of depres-
sion and fatigue, but analyses to determine risk factors have
typically lackedstatistical power. Thegoal of the current study
was to examine sociodemographic and clinical risk factors for
depression and fatigue in a large cohort of HCT survivors.
Methods: Measures of depression (Patient Health Ques-
tionnairee 8) and fatigue (Fatigue Symptom Inventory) were
included in the annual survey of HCT recipients transplanted
at Fred Hutchinson Cancer Research Center. The survey also
included self-reported sociodemographic, health, and
medication information. Patient clinical characteristics were
obtained from the clinical database. Analyses were con-
ducted using continuous outcomes.
Results: The sample consisted of 1869 recipients (mean age
56, 53% male) with complete depression and fatigue data
(response rate of 40.8%). A total of 13% of participants
reported moderate to severe depression; 42% reported
moderate to severe fatigue. Participants were a median of 8
years from transplant (range 0.5-40 years). Depression was
signiﬁcantly associated with fatigue severity (r¼.73,
p<.0001) and fatigue disruptiveness (r¼.80, p<.0001).
Univariate analyses indicated that female gender, younger
age, chronic pain, second malignancy, allogeneic HCT, and
receipt of peripheral blood stem cells (vs. bone marrow)
were associated with greater depression, fatigue severity,
and fatigue disruptiveness (p values < .05). Among
allogeneic recipients, self-reported current and past chronic
graft-versus-host disease (GVHD) symptomatology were
associated with increased depression, fatigue severity, and
fatigue disruptiveness (p values < .05). Extent of HLA match,
myeloablative regimen, total body irradiation dose, and
patient and donor cytomegalovirus status were not
associated with depression or fatigue (p values > .05).
Multiple regression analyses using signiﬁcant univariate
predictors in the full sample indicated that female gender,
younger age, chronic pain, and receipt of peripheral blood
stem cells were independently associated with greater
depression and fatigue (p values < .05).
Conclusions: Data from the current study indicate that
females, younger patients, thosewith chronic pain, and those
who received peripheral blood stem cells are at higher risk
for fatigue and depression. The relatively high rates of
depression and fatigue in this group of survivors suggest a
high symptom burden. Better screening, referral, and
interventions are needed.
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Background: Low socioeconomic status (SES) is associated
with worse overall survival (OS) and higher transplant-
related mortality (TRM) in unrelated donor (URD)
hematopoietic stem cell transplantation (HCT) recipients
(BBMT 2009, 15:1543). A homogeneous subset of patients
from the parent study was selected and consisted of URD
myeloablative (MA) HCT recipients transplanted for acute
myelogenous leukemia (AML) in ﬁrst complete remission
(CR1). Among this group, low SES was signiﬁcantly
associated with increased expression of the conserved
transcriptional response to adversity (CTRA) gene expression
proﬁle, previously identiﬁed as also overexpressed in other
populations under conditions of chronic stress or adversity.
The purpose of the current study is to identify whether
increased CTRA gene expression may be an immunobiologic
mechanism by which pre-existing factors, such as SES, may
impact HCT outcomes.
Methods: We analyzed whether low vs. high expression of
the CTRA gene proﬁle (53 inﬂammatory, interferon-related,
and antibody-related genes) in peripheral blood mono-
nuclear cells (PBMCs) from a population of 78 Caucasian
individuals between ages 20-59 who received an URD MA
HCT for AML in CR1 is associated with signiﬁcantly different
clinical outcomes. We used the Kaplan-Meier method to
assess association with leukemia free survival (LFS) and OS
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the association with neutrophil engraftment, acute and
chronic graft-versus-host disease, TRM, and relapse. Patient,
disease, and HCT-related characteristics were compared
by chi-square statistic for categorical variables and the
Kruskal-Wallis test for continuous variables.
Results: Increased expression of the CTRA gene proﬁle is
associated with increased relapse at 3 years post-HCT
(p¼.04; Figure 1) and decreased LFS overall (p¼.04; Figure 2).
There were no signiﬁcant outcome differences based on SES
in this sample. HCT recipients of high SES lived closer to the
transplant center (p<.001) while recipients with higher
CTRA gene expression proﬁles were younger (p¼.04) and
were infused with lower doses of peripheral blood cells
(p.02). All other patient, disease, and demographic
variables were equal between groups.
Conclusions: Exposure to socioeconomic adversity is
associated with a marked pro-inﬂammatory/anti-antiviral
shift in the PBMC transcriptome and this shift in gene
expression is reciprocally related to adverse clinical
outcomes including increased relapse and decreased LFS.67
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The NIH chronic GVHD (cGVHD) Consensus Project
Ancillary and Supportive Care Guidelines prescribe yearly
monitoring of bone mineral density (BMD) based on prac-
tices in other chronic diseases. We hypothesize that patients
with cGVHD have a high incidence of osteoporosis due to
additive risk factors including inﬂammation, hypogonadism,
malnutrition, and chronic steroid use. A large group of
cGVHD patients was analyzed to determine the prevalence of
osteoporosis and characterize risk factors.
258 cGVHD patients were enrolled in the NIH/NCI Natural
History protocol (NCT00092235), a cross-sectional study
where patients undergo a one-week comprehensive
evaluation including DEXA. T-scores were calculated at the
femoral neck (FN), lumbar spine (LS), and total hip (TH).
Osteoporosis was deﬁned by BMD (T-score -2.5). Patients
were placed into 2 groups, osteoporosis and non-
osteoporosis and analyzed for factors associated with
osteoporosis initially by standard univariate statistical tests;
p values<0.005 were considered statistically signiﬁcant
while tests with 0.005<p<0.05 exhibited strong trends
towards statistical signiﬁcance. Multivariable analyses were
performed using multiple logistic regression analysis.
Patients (145 M, 113 F) with median age of 48 years (20-
71), enrolled a median of 692 days (0-6670) after cGVHD
diagnosis, with a median of 5 affected organs (1-8), received
a median of 4 prior systemic therapies (0-9), and a medianequivalent prednisone dose of 0.078mg/kg (0-3.38). 183
patients (71%) had severe, 73 (28%) moderate, and 2 (1%)
mild cGVHD by NIH Global score. 42 (16%) patients had
osteoporosis in at least 1 location with incidence highest at
the FN (33; 13%) followed by LS (24; 9%) and TH (15; 6%).
Female gender (FN: p¼0.04), lower weight (FN: p<0.0001;
LS: p¼0.0002; TH: p<0.0001), higher platelet count (FN:
p¼0.007; TH: p¼0.003), higher NIH average organ score (FN:
p¼0.04), higher prednisone dose (LS: p¼0.03), and lower C3
(LS: p¼0.007) were associated with osteoporosis. Factors not
associated included age, vitamin D3, estradiol, FSH, LH,
testosterone, number of prior systemic therapies, among
others. Multiple logistic regression analyses determined that
BMI, prednisone dose, and number of prior regimens were
potentially predictive for spinal osteoporosis, while FN and
TH osteoporosis were potentially predictable by weight and
platelet counts.
Prevalence of osteoporosis was high (16%) which supports
current recommendations of regular BMD monitoring.
Classic risk factors such as age, hypogonadism, and steroid
use were not found to be signiﬁcantly associated, factors
reﬂecting more severe disease and inﬂammation such as low
weight and elevated platelets were found to be associated.
This suggests a need to focus on cGVHD control as a means to
prevent osteoporosis, a hypothesis which needs further
testing in prospective studies.68
The Impact of Oral Chronic Graft-Versus-Host Disease on
Global Measures of Quality of Life
Joseph DePalo 1, Xiaoyu Chai 2, Stephanie J. Lee 2,
Corey S. Cutler 3, Nathaniel Treister 4. 1Harvard School of
Dental Medicine, Boston, MA; 2 Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WA; 3Hematologic
Malignancies, Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA; 4Division of Oral Medicine and Dentistry,
Brigham and Women’s Hospital, Boston, MA
Chronic GVHD (cGVHD) is a frequent complication of
allogeneic hematopoietic stem cell transplantation (HSCT)
and affects multiple organ systems, with the oral cavity being
one of the most frequently affected sites. Patients with
cGVHD experience reduced quality of life (QOL), yet the
speciﬁc impact of oral cGVHD on QOL is poorly understood.
The objective of this study was to characterize the impact of
oral cGVHD on global measures of QOL.
Methods: QOL data were collected using the FACT-BMT and
SF-36 instruments for 569 patients enrolled in the Chronic
GVHD Consortium, with a total of 1,915 follow-up visits. At
study enrollment, patients were categorized as isolated oral
cGVHD (n¼22), oral and concomitant extra-oral cGVHD
(n¼420), and only extra-oral cGVHD (n¼127). Utilizing all
longitudinal data, QOL scores were compared using a
multivariable linear model controlling for demographic,
transplant, and cGVHD characteristics.
Results: Patients with isolated oral cGVHD reported better
physical well-being (P¼0.009), BMT well-being (P¼0.01),
and decreased bodily pain (P¼0.01) compared to patients
with oral and concomitant extra-oral cGVHD. A similar trend
was observed that patients with isolated oral cGVHD
reported better physical well-being (P¼0.02) and less bodily
pain (P¼0.02) compared to patients with only extra-oral
cGVHD. QOL scores were similar in several domains, most
notably social/family well-being, physical role functioning,
and vitality, when comparing patients with isolated oral
cGVHD to patients with oral and concomitant extra-oral
cGVHD and only extra-oral cGVHD.
